Two mid-stage immunology results shifted competitive dynamics in atopic dermatitis. Evommune reported EVO301 achieved a statistically significant Eczema Area and Severity Index (EASI) reduction versus placebo in a Phase IIa study, prompting a sharp share-price rally. The company says optimized dosing could deepen effects in follow-up trials. Nektar presented one-year maintenance data showing its IL-2–targeting candidate rezpeg sustained and in some cases deepened clinical responses when switched to less frequent dosing. Both firms signaled plans for larger confirmatory studies, underscoring investor appetite for agents that can compete with entrenched biologics such as Dupixent.